芦可替尼在血液恶性肿瘤与免疫介导疾病中的药代动力学及暴露-毒性关系:一项前瞻性观察研究
该研究纳入瑞士多中心77例成人患者,分析221份稳态芦可替尼血药浓度,用群体药代动力学模型评估清除率变异及协变量影响,并探索暴露-效应关系。结果显示清除率个体间变异达45%,强CYP3A4或双CYP2C9/CYP3A4抑制剂使清除率降低39%;10 mg每日两次时模拟显示CYP抑制剂使中位Cmin和AUC24分别升高2.9倍和1.7倍。未发现显著暴露-疗效关系,但较高暴露倾向于与毒性增加相关(Cmin和AUC24,P≈0.02-0.03)。
要点
- 芦可替尼清除率个体间变异大(45%),强CYP抑制剂使清除率降低39%。
- 10 mg每日两次时,CYP抑制剂使中位Cmin和AUC24分别升高2.9倍和1.7倍。
- 较高暴露倾向于与毒性增加相关,支持谨慎调整剂量。
核心结论
- 芦可替尼在临床实践中暴露变异大,强CYP抑制剂显著影响清除率,较高暴露与毒性风险增加相关,支持谨慎剂量调整。
研究设计与样本
- 前瞻性观察研究,纳入瑞士多中心77例成人患者,分析221份稳态芦可替尼浓度,采用MonolixSuite® 2024R1进行群体药代动力学分析。
主要发现
- 芦可替尼清除率个体间变异为45%。
- 强CYP3A4或双CYP2C9/CYP3A4抑制剂使清除率降低39%。
- 10 mg每日两次时,模型模拟显示CYP抑制剂使中位Cmin和AUC24分别升高2.9倍和1.7倍。
- 未发现显著暴露-疗效关系。
- 较高暴露倾向于与毒性增加相关(Cmin和AUC24,P≈0.02-0.03)。
临床怎么用
- 临床使用芦可替尼时应关注强CYP抑制剂合并使用,必要时调整剂量。
- 较高暴露可能增加毒性风险,需密切监测不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ruxolitinib pharmacokinetics (PK) has been characterized in clinical trials but remains poorly documented in real-world practice. This project aimed to investigate ruxolitinib PK in routine clinical practice, identify factors driving its variability, and explore exposure-response relationships to assess the potential role of therapeutic drug monitoring. In total, 221 steady-state ruxolitinib concentrations from 77 adult patients enrolled across several centers in Switzerland were analyzed. Demographic and clinical data were recorded at each visit. Population pharmacokinetic (popPK) analysis was performed with MonolixSuite® 2024R1 (Lixoft, France). Model-based simulations were used to predict trough concentration (Cmin) and the area under the concentration-time curve over 24 h (AUC24) for the recommended dosage regimens, as a function of covariates. An exploratory pharmacokinetic/pharmacodynamic analysis was conducted in the overall cohort. Ruxolitinib PK was characterized by a marked between-subject variability in clearance (45%). Strong cytochrome (CYP) 3A4 or dual CYP2C9/CYP3A4 inhibitors reduced clearance by 39%. At 10 mg twice daily, model-based simulations showed CYP inhibitors increased median Cmin and AUC24 by 2.9- and 1.7-fold, respectively. Still, no significant exposure-efficacy relationship was identified. However, higher ruxolitinib exposure tended to be associated with increased toxicity in the overall population (Cmin and AUC24, P≈0.02-0.03). In clinical practice, ruxolitinib exposure shows substantial variability and is strongly affected by strong CYP inhibitors that are frequently co-administered. Whilst no clear exposure-efficacy relationship was observed, higher exposure was linked to increased toxicity risk, arguing for careful dose adjustment.
引用
- Tachet J, Meyer SC, Grandoni F, et al. Ruxolitinib Pharmacokinetics and Exposure-Toxicity Relationship in Hematologic Malignancies and Immune-Mediated Diseases: A Prospective Observational Study. Clin Pharmacol Ther. 2026. PMID: 42338396. doi:10.1002/cpt.70367
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。